MedTrace Logo

Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy

NCT02786810 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-05-11

Study results available
· View outcomes & findings →

Summary

The study will be evaluating the efficacy and safety of a contrast drug in pediatric renal ultrasound.

Conditions

Interventions

DRUG

Sulfur hexafluoride type-a lipid microspheres

Used as a contrast to enhance renal ultrasound

Sponsors & Collaborators

  • University of Tennessee

    lead OTHER

Principal Investigators

  • David Hains, M.D. · University of Tennessee

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02786810 on ClinicalTrials.gov